Mitesh

Following representations made by Community Pharmacy England on behalf of community pharmacy owners, the Department of Health and Social Care (DHSC) has redetermined May and June 2026 reimbursement prices for the following products to reflect an increase in their NHS list prices. To avoid pharmacy owners dispensing these products at a loss, DHSC has agreed [...]

The post Retrospective reimbursement prices for May and June 2026 appeared first on Community Pharmacy England.

The Department of Health and Social Care (DHSC) has today (02/07/2026) confirmed the following final list of price concessions for June 2026: Drug Pack size Price concession Mirtazapine 15mg orodispersible tablets 30 £2.34 Mirtazapine 30mg orodispersible tablets 30 £2.40 Mirtazapine 45mg orodispersible tablets 30 £2.25 To date, this takes the total number of price concessions granted [...]

The post June 2026 Price Concessions Final Update appeared first on Community Pharmacy England.

5 new products have been added to the ‘Drugs for which Discount is Not Deducted’ (DND) list from 1 July 2026. Community Pharmacy England, on behalf of pharmacy owners, applied to the Department of Health and Social Care (DHSC) and the NHS Business Services Authority (NHSBSA) for these products to be added to the DND [...]

The post 5 products added to the Discount Not Deducted (DND) list from June 2026 appeared first on Community Pharmacy England.

MHRA Class 3 Medicines Recall: Flucloxacillin Capsules BP 500mg (Flamingo Pharma UK Ltd) Drug Alert Number: EL(26)A/32 Date issued: 30 June 2026 Flamingo Pharma UK Ltd have informed the MHRA that certain packs of Flucloxacillin Capsules BP 500mg contain the incorrect PIL. The affected packs contain the PIL for Amoxicillin 500mg Capsules instead of the PIL [...]

The post MHRA Class 3 Medicines Recall: Flucloxacillin Capsules BP 500mg (Flamingo Pharma UK Ltd) appeared first on Community Pharmacy England.

The product information for all ACE inhibitors is being updated to strengthen the warnings on the risk of delayed-onset angioedema, which may still occur after weeks to years of use. Healthcare professionals, particularly in emergency departments, should be aware of the potential for delayed onset of angioedema and the distinction between bradykinin- and histamine-mediated cases, [...]

The post MHRA Drug Safety Update: ACE-inhibitors appeared first on Community Pharmacy England.